Amsa: A phase II trial in resistant and recurrent acute myelogenous leukemia

Ralph V. Boccia(Center for Cancer and Blood Disorders), Robert Peter Gale(Imperial College London), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Jacob Zighelboim(University of California, Los Angeles), Chun Choo Kim(University of California, Los Angeles)
Medical and Pediatric Oncology
January 1, 1984
10.1002/mpo.2950120307
Cited by 5

Related Papers

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761